


From: Wendy McGuinness wmcg@mcguinnessinstitute.org 
Subject: OIA: Intensive care drugs
Date: 22 April 2020 at 5:41 PM
To:
Cc: oiagr@health.govt.nz, oiagr@moh.govt.nz

Good afternoon,

Please treat the following email as a request under the OIA. Given how busy you will be we have made the questions as specific as possible.

We have noted that intensive care drugs are in short supply globally (see for example in the UK – 12 April 2020: *Coronavirus: 'Local shortages' of intensive care drugs* <https://www.bbc.com/news/health-52150861>). We wonder whether New Zealand is in the same situation. To help provide clarity over this, would you be able to answer the following three questions:

1. Who is responsible for managing the stocktake of intensive care drugs in New Zealand?
2. What is 'the medical name' of all the intensive care drugs that are on the list to collect and store (especially those that are useful for treating patients with COVID-19)?
3. Please list the quantities that MoH has in stock of each 'intensive care drug' (especially those that are useful for treating patients with COVID-19)?

We consider this is important information given the government is moving to alert 3 before the virus is eliminated.

Thank you so much for your time.

Kind regards,
Wendy

Wendy McGuinness
Chief Executive

MCGUINNESS INSTITUTE

Level 2, 5 Cable Street, Wellington 6011 | PO Box 24-222 Wellington 6142
+64 4 499 8888 | wmcg@mcguinnessinstitute.org | www.mcguinnessinstitute.org

 [@McgInstitute](https://twitter.com/McgInstitute) |  [Follow us](#) |  [Watch us](#) | Connect with [TalentNZ](#) | Sign up for our [newsletter](#) | Join our [events list](#)

The McGuinness Institute is a non-partisan think tank working towards a sustainable future, contributing strategic foresight through evidence-based research and policy analysis.